Stockreport

Daré Bioscience Announces Publication in Obstetrics & Gynecology of Phase 2b Study Efficacy Results of Topical Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder

Dare Bioscience, Inc.  (DARE) 
Last dare bioscience, inc. earnings: 8/14 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.darebioscience.com/investor-relations
PDF Phase 2b study demonstrated topical Sildenafil Cream, 3.6% improved outcomes among women with female sexual arousal disorder (FSAD), particularly in an exploratory subse [Read more]